Earnings Preview: J&J to report 4th-qtr results

By LINDA A. JOHNSON - AP Business Writer - Associated Press Friday, January 22, 2024

Loading...

Johnson & Johnson, the world's largest, most diverse health care company and a Dow Jones industrial average component, reports earnings for the fourth quarter Tuesday. Here's a summary of key developments and analyst opinion related to the period.

OVERVIEW: A household name for its "No More Tears" baby shampoo, Band-Aids and Clean & Clear skin care line, Johnson & Johnson had a difficult quarter. The New Brunswick, N.J.-based company announced its second major restructuring in 2 1/2 years and a still-expanding recall of Tylenol and other popular consumer brands.

In addition, the Food and Drug Administration for a second time rejected J&J's experimental antibiotic ceftobiprole, for complicated skin infections like MRSA, in December, saying it will require additional studies.

The Tylenol recall, first announced in November, has twice been expanded and now includes products in the Motrin, Benadryl, Rolaids, St. Joseph's aspirin and Simply Sleep lines. The items have a mildew-like odor associated in some cases with nausea, stomach pain and vomiting.

The restructuring, J&J's biggest ever, aims to pare expenses by roughly $1.5 billion a year after 2011 and to address declines in sales of a couple of blockbuster prescription drugs with generic competition and lower consumer product sales because of the recession. Total revenue fell 5 percent in the third quarter, marking an unprecedented four straight quarters with revenue down significantly, after years of steady sales and profit increases.

The company said it will pare its work force by up to 8,000 jobs, or nearly 7 percent of the worldwide staff, over the next few years. Last August, J&J said it was consolidating management, starting by eliminating executive posts at its comprehensive care division. A restructuring begun in July 2007 eliminated roughly 4 percent of jobs.

Two bright spots during the quarter were acquisitions: Acclarent, which makes devices for minimally invasive treatment of ear, nose and throat disorders, for $785 million; and Gloster Europe, which makes decontamination technology to prevent hospital patients from catching infections. Terms of that deal were not disclosed.

BY THE NUMBERS: Analysts polled by Thomson Reuters expect, on average, earnings per share of 97 cents and revenue of $15.71 billion. A year earlier, J&J earned 97 cents per share on revenue of $15.2 billion.

ANALYST TAKE: Credit Suisse analyst Catherine Arnold raised her 2009 and 2010 earnings-per-share estimates by 2 cents and 9 cents, to $4.58 and $4.93, respectively. She also raised her 12-month target price for the stock to $71 from $61, well above J&J's current price near $64, citing factors including the company's high cash flow compared to competitors.

Arnold expects earnings growth from the pharmaceutical business to accelerate, driven by a "newer mix of products," and thinks investors have been focusing on that business's future. Still, she says, growth and diversification from the consumer and devices businesses have boosted share price. She had expected ceftobiprole to generate $350 million in U.S. sales alone by 2015, but has eliminated that, implying it won't get approved.

UBS analyst Bruce Nudell sets his price target at $70 a share.

"We continue to like (Johnson & Johnson) shares based on accelerating top-line growth that should in turn drive" higher earnings per share, he writes. Nudell thinks the recovery from the recession "should bode well" for the consumer and devices businesses, while new products should boost the prescription drugs business.

Elsewhere, analyst Steve Brozak of WBB Securities expects to see another drop in quarterly sales.

"J&J is actually in a better position than any of their brethren, in that they have significant cash flow from their consumer health division," Brozak adds.

He says that gives the company flexibility in what it can afford to acquire, but Johnson & Johnson needs to be buying more companies.

"They need to ... announce four deals every quarter in 2010," compared to the four major acquisitions and partnerships they announced in all of 2009, which were "simply not enough" to sustain the growth shareholders expect, Brozak says.

WHAT'S AHEAD: The company is awaiting the outcome of the troubled health care overhaul as well as rulings from the FDA on whether it will approve several products.

Those include Sedasys, a computerized sedation system for patients getting diagnostic procedures; the Pinnacle Complete hip-implant system, a ceramic-on-metal design meant to last longer and give freer motion than metal-on-metal artificial joints; anti-clotting drug rivaroxaban and an extended-release version of Nucynta, a pill for moderate-to-severe chronic pain.

However, the FDA, stung by increasing criticism over drug safety issues the past couple years, has required more data on patient survival from studies of a fifth product, Yondelis for ovarian cancer.

Meanwhile, J&J's arbitration battle with Merck & Co. over rights to foreign sales of blockbuster biotech drug Remicade, for rheumatoid arthritis and other immune disorders, and successor drug Simponi is dragging on. The dispute started when Merck acquired Schering-Plough Corp., with whom J&J jointly sold the drugs. An arbitration panel has been selected, but a hearing won't be held until September.

STOCK PERFORMANCE: Shares rose 5.8 percent to $60.41 during the fourth quarter. For all of 2009, shares rose 7.7 percent.

Join the Discussion
Rate Article: Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Research Exchange

Publishing Data That Conform to the MIQE Guidelines

Jan 22

Minimum information for publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines help researchers design qPCR experiments.

Calibration Free Analysis to Measure the Concentration of Active Proteins

Nov 23 2009

An SPR-based method, Calibration Free Concentration Analysis can be used to accurately determine the concentration of active protein in a sample, relating to the specific binding activity of the protein, and without the need for a standard.

Advances in EMCCD Technology: Making Imaging Less Arbitrary

Nov 16 2009

Recent advances in EMCCD technology have solved the problem of non-standardized measurement units by using the photoelectron to standardize imaging experiments.

10 Tips for Successful Sample Concentration and Buffer Exchange

Nov 6 2009

Centrifugal devices with ultrafiltration (UF) membrane can solve common problems researchers face when working with proteins.

Advantages of Monolithic Laser Combiner Technology in Confocal Microscopy Systems

Jan 6

Fluorescence microscopy techniques require a reliable light source at the desired wavelength or wavelengths, with minimal downtime for maintenance and alignment. Lasers are a popular light source, although the alignment and upkeep of laser combiners is a time-consuming prospect for many users.

Size-Exclusion Chromatography for Purification of Biomolecules

Dec 2 2009

Size-exclusion chromatography (SEC) is a popular method to separate biomolecules based on their size. Primarily, it is applied to the separation of biopolymers such as proteins and nucleic acids, i.e. water-soluble polymers.

Improving Separation During Electrophoresis

Dec 2 2009

SeparateIT gels represent a novel gel matrix for DNA electrophoresis. Gel polymers are arranged in a conceptually different way, in accordance with a new theoretical model of gel electrophoresis.

Improving Quality of ELISA

Dec 2 2009

Using ready-to-use ELISA kits from manufacturers is easy and convenient. Sometimes however, home-made ELISA is required because there is no kit available with the right antibodies or the characteristics of the available kits such as their limits of detection are not appropriate.

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Nov 9 2009

Action selection is modulated by external stimuli either directly or via memory retrieval. In a constantly changing environment, animals have evolved attention-like processes to effectively filter the incoming sensory stream. These attention-like processes, in turn, are modulated by memory. The neurobiological nature of how attention, action selection and memory are inter-connected is unknown. We describe here new phenotypes of the memory mutant radish in the fruit fly Drosophila.

Mechanisms of plasticity in simple taxis behaviors in Drosophila

Nov 8 2009

Like the proverbial moth drawn to the candle flame, the fruit fly Drosophila also stereotypically approaches light sources. This positive phototaxis is the archetypal example of hard-wired input-output behaviors.

Live cell imaging of mutant and wild-type GABA-A receptor trafficking using a novel reporter protein

Nov 8 2009

Efficient signaling in the brain requires precise regulation and targeting of cell surface ion-channels. Mutations in these channels associated with inherited diseases can cause improper targeting and reduced surface expression.

ADP-Glo™: An Ideal Approach to Monitor the Activity of Protein Kinases and Beyond

Oct 16 2009

Because of its versatility (alltypesofsubstrates), robustness (Z’>0.8), rapidperformance, and its ease of use, the luminescence based Kinase Glo® assay platform has gained wide acceptance in many drug screening programs for protein kinase inhibitors.

Erroneous automated optical platelet counts in 1-hour post-transfusion blood samples.

Jan 23

Summary Thrombocytopenic patients with acute leukemia may show high post-transfusion count increments that significantly exceed the number of transfused platelets. This study demonstrates that the automated hematology analyzer Sysmex XE-2100 reports erroneously high optical...

Evaluation of a capillary blood collection system for screening for hemoglobinopathies in remote areas.

Jan 23

Summary Accurate estimation of hemoglobin (Hbs) A, Hb A(2), Hb F and abnormal Hb is required for diagnosis of hemoglobinopathies and genetic counseling. High pressure liquid chromatography (HPLC) is the most suitable approach available. But for 70% of the rural Indian...

Multiplex fluorescence in situ hybridization in identifying chromosome involvement of complex karyotypes in de novo myelodysplastic syndromes and acute myeloid leukemia.

Jan 23

Summary Complex chromosomal aberrations (CCA) can be detected in a substantial proportion of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), which are associated with very poor prognosis. Conventional cytogenetics (CC) cannot accurately define the specific...

Prokariotic Cell Collection in Denmark

Nov 6 2009

I would like to know about a prokariotic cell collection in Denmark. Is there a cell bank in this country? I need a Lactobacillus strain for a fermentation assay and this information about the bank is very helpful for me.

Request for Entries

Oct 16 2009

Ask the Experts is your chance to get the answers to questions on applications, materials, methods, processes, and technologies. Email you question to bst_web@advantagemedia.com, and the editors of Bioscience Technology will find an appropriate expert to answer it. Watch this space in the future to see the questions your colleagues are posting.

STAY INFORMED: SUBSCRIBE TO

Magazine and E-mail Newsletters

Loading...
E-mail:   

MULTIMEDIA

Video:

Neuroscience Diseases of The Brain and How The Mind Emerges

Neuroscience Diseases of The Brain and How The Mind Emerges

Nov 8 2009

Dennis Choi, director of Emory Universitys Neuroscience Center, is renowned for his groundbreaking research on brain and spinal cord injury.

Podcasts:

Allen Institute for Brain Research

Allen Institute for Brain Research

Oct 14 2009

Discussed in this interview are both the mouse brain project and the human cortex project with an emphasis on the importance of these projects to neuroscience research.

Information: